Scinovex
article Open AccessTop 1% cited

Lipoprotein(a) as a cardiovascular risk factor: current status

European Heart Journal · 2010 · Vol. 31(23) · pp. 2844–2853
Børge G. NordestgaardM. John ChapmanKausik K. RayJan BorénFelicita AndreottiGerald F. WattsHenry N. GinsbergPierre AmarencoAlberico L. CatapanoOlivier DescampsEdward A. FisherPetri T. KovanenJan Albert KuivenhovenPhilippe LesnikL. MasanaŽeljko ReinerMarja‐Riitta TaskinenLâle TokgözoğluAnne Tybjærg‐Hansen

Abstract

We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.

Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismDiabetes, Cardiovascular Risks, and LipoproteinsMedicineNiacinLipoprotein(a)Internal medicineApolipoprotein BRisk factorCardiologyLipoproteinCholesterolHomocysteine

MeSH terms

Age FactorsAnimalsCardiovascular DiseasesCoronary DiseaseFemaleHumansHyperlipoproteinemiasImmunoassayMaleMice, TransgenicRisk FactorsSex FactorsLipoprotein(a)Patient SelectionEarly Diagnosis

Funding

  • AstraZeneca
  • Kowa Company
  • European Atherosclerosis Society
Citations
1,758
FWCI
70.88
field-weighted impact
References
55
Percentile
100%
vs. same field & year
Citations per year
Cited by
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Atherosclerosis · 2016 · 1,581 citations
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
European Heart Journal · 2016 · 3,169 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.